Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 3.93 Cheap vs history 3rd percentile
5-year average 5.49 · #53 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 22.34 Cheap vs history 8th percentile
5-year average 98.52 · forward 15.56 · #14 of 26 in Drug Manufacturers - Specialty & Generic
P/S ratio 4.12 Cheap vs history 1st percentile
5-year average 6.25 · forward 3.39 · #53 of 79 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Neurocrine Biosciences (NBIX) 15.24B 22.34 3.93 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value165.22 Economic moatNarrow UncertaintyMedium

Trading 9.7% below Morningstar's fair value estimate.

Fair value

Neurocrine Biosciences Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% discount to our quantitative fair value estimate of $165.22 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's solid growth strengthens our fair value estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 28.3%, which sits in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.0, a core component of valuation, falls in the bottom 40% compared with global peers. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment